Whois & Analysis for xeljanz.com

Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum.

The primary symptom of active disease is abdominal pain and diarrhea mixed with blood.

Weight loss, fever, and anemia may also occur.

Often symptoms come on slowly and can range from mild to severe.

Symptoms typically occur intermittently with periods of no symptoms between flares.

Complications may include megacolon, inflammation of the eye, joints, or liver, and colon cancer.

Psoriatic arthritis is a long-term inflammatory arthritis that occurs in people affected by the autoimmune disease psoriasis.

The classic feature of psoriatic arthritis is swelling of entire fingers and toes with a sausage-like appearance.

This often happens in association with changes to the nails such as small depressions in the nail (pitting), thickening of the nails, and detachment of the nail from the nailbed.

Skin changes consistent with psoriasis (e.g., red, scaly, and itchy plaques) frequently occur before the onset of psoriatic arthritis but psoriatic arthritis can precede the rash in 15% of affected individuals.

It is classified as a type of seronegative spondyloarthropathy.

Tofacitinib (INN) is a drug of the janus kinase (JAK) inhibitor class, discovered and developed by the National Institutes of Health and Pfizer.

Tofacitinib is marketed as Xeljanz and Jakvinus.

Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints.

It typically results in warm, swollen, and painful joints.

Pain and stiffness often worsen following rest.

Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body.

The disease may also affect other parts of the body.

This may result in a low red blood cell count, inflammation around the lungs, and inflammation around the heart.

Fever and low energy may also be present.

Often, symptoms come on gradually over weeks to months.

In pharmacology, bioavailability (BA) is a subcategory of absorption and is the fraction of an administered dose of unchanged drug that reaches the systemic circulation, one of the principal pharmacokinetic properties of drugs.

By definition, when a medication is administered intravenously, its bioavailability is 100%.

However, when a medication is administered via other routes (such as orally), its bioavailability generally decreases (due to incomplete absorption and first-pass metabolism) or may vary from patient to patient.

Bioavailability is one of the essential tools in pharmacokinetics, as bioavailability must be considered when calculating dosages for non-intravenous routes of administration.